Abstract:Objective Cardioneuroablation (CNA) is effective for cardiac inhibitory and mixed vasovagal syncope (VVS) but not vasodepressor VVS. This study aimed to assess the therapeutic benefits of CNA in vasodepressor VVS. Methods VVS patients hospitalized in the Department of Cardiology of Jiangxi Provincial People’s Hospital were retrospectively reviewed. Holter monitoring was performed before, during, and 3 months after CNA. Changes in heart rate and Wenckebach point of atrioventricular conduction before and after ablation were compared. Results Thirty-five patients were enrolled, 18 men and 17 women. Mean age was 47.48 ± 16.49 years. Median duration of syncope was 24.0 months (range, 2.5–66.0). Median number of syncope episodes before treatment was two (range, 2–4). The time domain indexes of heart rate variability, mean heart rate, maximum heart rate, and minimum heart rate were significantly higher 3 months after CNA. Mean follow-up was 11 ± 4.67 months. Recurrent syncope occurred in two patients with vasodepressor VVS, one of them with presyncope symptoms in vasodepressor type; and one patient occurred with mixed VVS, without presyncope symptoms. No serious complications occurred. CNA is safe and effective in the treatment of vasodepressor VVS. Conclusions CNA is effective for treating vasodepressor VVS. Our study provides a theoretical basis for individualization of treatment in patients with vasodepressor VVS. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial This is a retrospective study ### Funding Statement This work was supported by grants from the National Natural Science Foundation of China (82000276), Supported by Administration of Traditional Chinese Medicine of Jiangxi Province (2020A0148), Grant for Science and Technology Project of Jiangxi Provincial Health Commission (202310005). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics Committee of Jiangxi Provincial People's Hospital I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Cardioneuroablation for Drug Refractory Vasovagal Syncope After COVID-19 Infection

Selective Anatomical Catheter Ablation of Left Atrial Ganglionated Plexus for Vasovagal Syncope: Left Superior and Right Anterior Ganglionated Plexus Ablation

Cardioneuroablation for Treating Vasovagal Syncope: Current Status and Future Directions

Cardioneuroablation as a strategy to prevent pacemaker implantation in young patients with vasovagal syncope

Cardioneuroablation in Patients with Vasovagal Syncope:An updated systematic review and meta-analysis

Cardioneuroablation for Cardioinhibitory Vasovagal Syncope: Rationale, Approaches, and Its Role in Long-Term Management

Cardioneuroablation for vasovagal syncope: insights on patients' selection, centre settings, procedural workflow and endpoints-results from an European Heart Rhythm Association survey

Efficacy of Cardioneurablation for Vasodepressor Vasovagal Syncope

Cardioneuroablation for vasovagal syncope and atrioventricular block: A step‐by‐step guide

Clinical Efficacy of Catheter Ablation in the Treatment of Vasovagal Syncope

Cardioneuroablation for the management of patients with recurrent vasovagal syncope and symptomatic bradyarrhythmias: the CNA-FWRD Registry

Cardioneuroablation: the known and the unknown

Cardioneuroablation for the management of neurally mediated syncope, sinus bradycardia, and atrioventricular block

The benefit of cardioneuroablation to reduce syncope recurrence in vasovagal syncope patients: a case-control study

Ganglionated Plexus Ablation Procedures to Treat Vasovagal Syncope

Effectiveness of cardioneuroablation in different subtypes of vasovagal syncope

Simplified Cardioneuroablation in the Treatment of Reflex Syncope, Functional AV Block, and Sinus Node Dysfunction

Long‐term outcomes of cardioneuroablation with and without extra‐cardiac vagal stimulation confirmation in severe cardioinhibitory neurocardiogenic syncope

Diagnosis and treatment of recurrent syncope in a middle‐aged women

Potential consequences of cardioneuroablation for vasovagal syncope: A call for appropriately designed, sham-controlled clinical trials

Cardioneuroablation can be an effective strategy to treat glossopharyngeal neuralgia‐related sinus bradycardia and pauses